BioCryst (BCRX) Files Form 144 for 70K Common Shares on NASDAQ

Rhea-AI Filing Summary

BioCryst Pharmaceuticals (BCRX) Form 144 notifies a proposed sale of 70,000 common shares through Fidelity Brokerage Services with an aggregate market value of $595,870.74. The shares are scheduled for sale on 08/13/2025 on NASDAQ and come from a reported total outstanding share count of 209,920,430.

The filing shows the shares derive from stock options: 30,000 from an option granted 05/29/2019 and 40,000 from an option granted 05/12/2020, with the consideration listed as cash. The filer reports Nothing to Report for sales in the past three months and includes the standard representation that no undisclosed material adverse information is known to the seller.

Insights

Securities Analyst

TL;DR Routine Form 144 for 70,000 shares, representing ≈0.033% of outstanding shares; likely immaterial to market capitalization.

The Form 144 discloses a proposed sale of 70,000 common shares through Fidelity with an aggregate market value of $595,870.74 and an outstanding share count of 209,920,430. Based on those figures, the proposed sale represents roughly 0.033% of outstanding shares, a very small fraction unlikely to move the stock materially on its own. The filing indicates the shares stem from option grants dated 05/29/2019 (30,000 shares) and 05/12/2020 (40,000 shares) and lists payment as cash. The filer reports no sales in the past three months.

Corporate Governance Expert

TL;DR Disclosure appears procedural and consistent with Rule 144; some form fields are unpopulated in the provided text.

The notice supplies required transaction details—broker, number of shares, aggregate value, acquisition provenance (stock options), and planned sale date—consistent with compliance expectations for a Rule 144 notice. In the version provided, heading fields such as the issuer name block and the date/signature lines are shown but contain no populated values, as displayed in the content. That omission may reflect how the content was captured rather than substance about the sale itself. Overall, the disclosure is routine and the filing is not a material corporate event.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	70000	595870.74	209920430	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/13/2025	Option Granted - 05/29/2019	Issuer			30000	08/13/2025	Cash
Common	08/13/2025	Option Granted - 05/12/2020	Issuer			40000	08/13/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many BioCryst (BCRX) shares are proposed to be sold in this Form 144?

The filing lists a proposed sale of 70,000 common shares with an aggregate market value of $595,870.74.

When is the approximate sale date for the shares listed on the Form 144?

The Form 144 indicates an approximate date of sale of 08/13/2025.

Which broker and exchange are referenced for the proposed sale?

The broker is Fidelity Brokerage Services LLC (address shown) and the exchange listed is NASDAQ.

How were the securities acquired according to the filing?

The securities derive from stock options: 30,000 from an option granted 05/29/2019 and 40,000 from an option granted 05/12/2020; payment is listed as cash.

Has the filer sold any securities of the issuer in the past three months?

The filing reports Nothing to Report for securities sold during the past three months.